Neuren Pharmaceuticals' (ASX:NEU) Jon Pilcher speaks to Proactive's Andrew Scott following the news they've received approval for the final stage of its NNZ-2591 clinical trial. The Phase 1 trial in Australia is evaluating the safety, tolerability and pharmacokinetics of the drug in healthy adult volunteers before advancing to Phase 2 trials in patients next year.
Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial
Quick facts: Neuren Pharmaceuticals Ltd
Price: 1.25 AUD
Market Cap: $147.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Neuren Pharmaceuticals Ltd named herein, including the promotion by the Company of Neuren Pharmaceuticals Ltd in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE